Last reviewed · How we verify
NCT03465319
Evaluation of the Concentration-prediction for Oxygen and Volatile Anesthetic Agents in the 'Draeger Perseus A500' Anesthesia Machine
trial in Anesthesia in 20 participants. Completed in 10 January 2017.
10 January 2017
Quick facts
| Lead sponsor | University of Erlangen-Nürnberg Medical School |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 15 December 2015 |
| Primary completion | 10 January 2017 |
| Estimated completion | 10 January 2017 |
| Sites | 1 location across Germany |
Conditions studied
- Anesthesia — all drugs for Anesthesia →
Sponsor
University of Erlangen-Nürnberg Medical School
Who can join
Adults 20 to 60, any sex, with Anesthesia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The anesthesia machine "Draeger Perseus A 500" has an integrated software which calculates the predicted course of the concentration of oxygen and the volatile anesthetics sevoflurane and desflurane for the next 20 minutes. The Goal of this study was to evaluate the accuracy of this prediction under controlled clinical circumstances. Therefore 20 patients undergoing an operation with general anesthesia were included. They were assigned to a sevoflurane- or desflurane-group by lots. The oxygen- and volatile anesthetic influx into the anesthesia machine's circuit was adjusted following a fixed protocol. The concentration of oxygen and the volatile anesthetic was measured and compared to the predicted values.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03465319
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Anesthesia
Currently open trials in the same condition.
- NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
- NCT07290205 — Remimazolam NeuroImaging · EARLY_PHASE1 · recruiting
- NCT07465185 — Intrathecal Bupivacaine With or Without Dexmetomidine for Cesserian Delivery · Phase 2 · recruiting
- NCT07269808 — Sedation During Endoscopy Using Remimazolam: Efficacy in a Novel Exploration · Phase 3 · recruiting
- NCT07443254 — Prospective IR-led Sedation Feasibility · Phase 1, PHASE2 · recruiting
Other University of Erlangen-Nürnberg Medical School trials
Trials by the same sponsor.
- NCT06969820 — Establishment and Evaluation of Standardized Clinical, Biological and Imaging Parameters to Assess the Response of LDRT · not yet recruiting
- NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
- NCT07352540 — Single vs Triple Hyaluronic Acid in Knee Osteoarthritis · Phase 2, PHASE3 · not yet recruiting
- NCT07313878 — Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Micros · NA · recruiting
- NCT07121985 — Multispectral Optoacoustic Imaging for the Detection of Inflammation and Damage of Peripheral Nerves in Guillain-Barré S · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03465319 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Erlangen-Nürnberg Medical School
- Last refreshed: 16 March 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03465319.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing